Difference between revisions of "Atypical small acinar proliferation"

From Libre Pathology
Jump to navigation Jump to search
(split out)
Line 20: Line 20:
*Atypical appearing acini.
*Atypical appearing acini.
*Limited extent - '''key feature'''.
*Limited extent - '''key feature'''.
**Less than six glands.
**Less than six glands.


Note:
Note:
*Deeper cuts didn't yield anything - '''important'''.
*Deeper cuts didn't yield anything - '''important'''.
*† There is no agreed upon minimum number of glands; however, one paper suggests that agreement among experts is low with 5 or less glands.<ref name=pmid20061936>{{Cite journal  | last1 = Van der Kwast | first1 = TH. | last2 = Evans | first2 = A. | last3 = Lockwood | first3 = G. | last4 = Tkachuk | first4 = D. | last5 = Bostwick | first5 = DG. | last6 = Epstein | first6 = JI. | last7 = Humphrey | first7 = PA. | last8 = Montironi | first8 = R. | last9 = Van Leenders | first9 = GJ. | title = Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. | journal = Am J Surg Pathol | volume = 34 | issue = 2 | pages = 169-77 | month = Feb | year = 2010 | doi = 10.1097/PAS.0b013e3181c7997b | PMID = 20061936 }}</ref>


DDx:
DDx:

Revision as of 01:29, 18 March 2014

Atypical small acinar proliferation, abbreviated ASAP, is a small number of prostate glands that are abnormal and suspicious for carcinoma.

It is also known as suspicious for carcinoma.[1] ASAP is preferred as it does not contain the word carcinoma and, thus, cannot be misread as carcinoma, i.e. positive for malignancy.

General

  • It is a waffle diagnosis, i.e. it is not considered an entity with a distinct pathobiology.[2]
    • Analogous to ASCUS on a pap test.
  • ASAP should be used sparingly.
    • One benchmark is < 3-5% of biopsies.[3]
  • Never diagnosed on excision, i.e. prostatectomy specimen.

Association with adenocarcinoma

Management

  • ASAP is considered an indication for re-biopsy;[5] in one survey of urologists[6] 41/42 (~98%) of respondents considered it a sufficient reason to re-biopsy.

Microscopic

Features:

  • Atypical appearing acini.
  • Limited extent - key feature.
    • Less than six glands.†

Note:

  • Deeper cuts didn't yield anything - important.
  • † There is no agreed upon minimum number of glands; however, one paper suggests that agreement among experts is low with 5 or less glands.[7]

DDx:

IHC

  • Generally not contributory.

Usually stains like cancer:

  • AMACR +ve.
  • CK34betaE12 -ve.
  • p63 -ve.

See also

References

  1. THvdK. 19 June 2010.
  2. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D (January 2007). "Atypical small acinar proliferation: biopsy artefact or distinct pathological entity". BJU International 99 (4): 780-5. PMID 17378841. http://www3.interscience.wiley.com/journal/118508438/abstract.
  3. THvdK. 19 June 2010.
  4. Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M (June 2008). "Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy". Clinics 63 (3): 339–42. PMID 18568243. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000300009&lng=en&nrm=iso&tlng=en.
  5. Bostwick DG, Meiers I (July 2006). "Atypical small acinar proliferation in the prostate: clinical significance in 2006". Arch. Pathol. Lab. Med. 130 (7): 952–7. PMID 16831049. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=130&page=952.
  6. Rubin MA, Bismar TA, Curtis S, Montie JE (July 2004). "Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?". Am. J. Surg. Pathol. 28 (7): 946–52. PMID 15223967.
  7. Van der Kwast, TH.; Evans, A.; Lockwood, G.; Tkachuk, D.; Bostwick, DG.; Epstein, JI.; Humphrey, PA.; Montironi, R. et al. (Feb 2010). "Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.". Am J Surg Pathol 34 (2): 169-77. doi:10.1097/PAS.0b013e3181c7997b. PMID 20061936.